10/12/2025
๐จ ๐๐๐ฐ๐ฌ ๐๐ฉ๐๐๐ญ๐: ๐๐ ๐๐ง๐ญ๐ซ๐จ๐๐ฎ๐๐๐ฌ ๐๐๐ฐ ๐๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ฎ๐ข๐๐๐ฅ๐ข๐ง๐ ๐๐๐๐จ๐ฆ๐ฆ๐๐ง๐๐ข๐ง๐ ๐๐ก๐๐ซ๐ฆ๐๐๐จ๐ ๐๐ง๐๐ญ๐ข๐ ๐๐๐ฌ๐ญ๐ข๐ง๐ ๐๐๐
๐๐๐ ๐๐ซ๐๐ฌ๐๐ซ๐ข๐๐ข๐ง๐ ๐๐ฅ๐จ๐ฉ๐ข๐๐จ๐ ๐ซ๐๐ฅ
The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (UK-CERSI-PGx), led by the University of Liverpool, now recommends that all patients undergo ๐๐๐๐๐๐๐ ๐ ๐๐ง๐จ๐ญ๐ฒ๐ฉ๐ข๐ง๐ before starting Clopidogrel to ensure optimal drug response.
Refer to the news here: https://pharmaceutical-journal.com/article/news/all-patients-should-undergo-pharmacogenetic-testing-before-being-prescribed-clopidogrel
This is a major step toward precision-guided antiplatelet therapy. It is particularly important for ๐๐ฌ๐ข๐๐ง ๐ฉ๐จ๐ฉ๐ฎ๐ฅ๐๐ญ๐ข๐จ๐ง๐ฌ, where up to ๐๐โ๐๐% may carry CYP2C19 variants that can impair Clopidogrel metabolism. At Precision Diagnostic, our recent collaborative research with the National University of Singapore and the Malaysian Pharmacists Society, presented at the FIP World Congress, indicates that ๐ ๐ข๐ง ๐๐ ๐๐๐ฅ๐๐ฒ๐ฌ๐ข๐๐ง ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ would benefit from genotype-informed Clopidogrel decisions.
Understanding the importance of pharmacogenomics (PGx) as a pre-emptive tool in medication selection, Precision Diagnostic formalised a ๐๐๐ฆ๐จ๐ซ๐๐ง๐๐ฎ๐ฆ ๐จ๐ ๐๐ง๐๐๐ซ๐ฌ๐ญ๐๐ง๐๐ข๐ง๐ (๐๐จ๐) with ๐๐ซ๐จ๐๐๐ฌ๐ฌ๐จ๐ซ ๐๐ข๐ซ ๐๐ฎ๐ง๐ข๐ซ ๐๐ข๐ซ๐ฆ๐จ๐ก๐๐ฆ๐๐, ๐๐๐ง๐ญ๐ซ๐ ๐๐๐๐ ๐๐ญ ๐ญ๐ก๐ ๐๐ง๐ข๐ฏ๐๐ซ๐ฌ๐ข๐ญ๐ฒ ๐จ๐ ๐๐ข๐ฏ๐๐ซ๐ฉ๐จ๐จ๐ฅ. This is the same centre that is now leading the new UK Clopidogrel guideline.
Through this partnership, we are collaborating on an international DPYD pharmacogenomics study to improve the safety of fluoropyrimidine-based cancer treatments and reduce toxicity risks across Asian communities.
With the UK now adopting PGx-guided prescribing for Clopidogrel, we are encouraged to continue advancing similar evidence-based precision approaches across Malaysia and Asia. Our ongoing collaboration with Prof Sir Munir brings us closer to that goal.
Together, we are advancing safer, smarter, and more personalised treatment pathway. ๐๐ก
A UK-first guideline has recommended that all patients should have pharmacogenetic testing to identify clinically relevant CYP2C19 genetic variants, regardless of indication. The clinical guideline, published by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (UK...